Call for Abstract
International Pharmacy Conference, will be organized around the theme “Innovations in Exertions of Pharmacy”
Pharmacy 2016 is comprised of 16 tracks and 111 sessions designed to offer comprehensive sessions that address current issues in Pharmacy 2016.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
The confines of pharmacy practice includes more traditional roles such as compounding and dispensing medications, and it also includes more current services related to health care, including clinical services, reviewing medications for safety and efficacy, and implement drug information. Pharmacists, therefore, are the experts on drug therapy and are the primary health professionals who amend use of medication for the benefit of the patients.
The global market for anti-counterfeiting packaging technologies is expected to increase from nearly $74.2 billion in 2015 to $135.6 billion in 2020, with a compound annual growth rate (CAGR) of 12.8% from 2015 to 2020.
- Track 1-1Disease State Management
- Track 1-2Prevention of Drug Reactions
- Track 1-3Clinical Intervention of Drugs
- Track 1-4Drug Incompatibity
- Track 1-5Interprofessional Collaborations in Pharmacy Practice
- Track 1-6Organizing Drug and Poison Information Centres
- Track 1-7e-Prescription
- Track 1-8Social and Administrative Pharmacy
Prepares medications by reviewing and construe physician orders; detecting therapeutic incompatibilities. Dispenses medications by compounding, packaging, and classify pharmaceuticals. Controls medications by monitoring drug therapies; advising interferens. Completes pharmacy operational requirements by organizing and directing technicians' work flow; verifying their preparation and labeling of pharmaceuticals; authenticating order entries, charges, and inspections. Provides pharmacological information by answering questions and requests of health care professionals; counselling patients on drug therapies.
The global market for single-use technologies for biopharmaceuticals was valued at $720 million in 2011 and should reach $985.2 million in 2012. Total market value is expected to reach nearly $2.4 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.1%.
- Track 2-1Pharmacotherapy
- Track 2-2Pharmacy Informatics
- Track 2-3Pharmacy Vision and Leadership
- Track 2-4Pharmacy Information Systems
- Track 2-5Bio-Pharmaceutics
Pharmacy is the science and conduct of preparing and dispensing drugs. It is a health profession that links health sciences with chemical sciences and aims to assure the safe and effective use of Pharmaceutical drug.Analysis and the future direction of treatments for neurodegenerative (i.e., progressive ataxia and weakness) disorders as the market efforts toward drug and therapy development evolve. Coverage of approved human antifungal therapeutics with a heavy focus on therapeutics in early development. Profiles of manufacturers of leading asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. Comprehensive analysis of the market for genitourinary drugs on a global basis
- Track 3-1Hospital Pharmacy
- Track 3-2Nuclear Pharmacists
- Track 3-3Nutrition Support Pharmacists
- Track 3-4Oncology Pharmacists
- Track 3-5Poison control Pharmacists
- Track 3-6Pharmacology
- Track 3-7Medicinal Chemistry
- Track 3-8Pharmacogenetics
- Track 3-9Pharmacotherapy
- Track 3-10Home Care Pharmacists
- Track 3-11Drug Information Pharmacists
- Track 3-12Clinical Pharmacy
- Track 3-13Consultant Pharmacy
- Track 3-14Veterinary Pharmacy
- Track 3-15Military Pharmacy
- Track 3-16Academic Pharmacists
- Track 3-17Ambulatory Pharmacists
- Track 3-18Compounding Pharmacists
- Track 3-19Critical Care Pharmacists
- Track 3-20Pharmaceutics
A clinical trial is a research study organizes to investigate new treatments such as a new drug compound inhuman volunteers or research participants. Each clinical trial is arranged to learn about a potential treatment and its effect on humans. Before a new treatment is tried in human, considerable laboratory testing are done to identify promising compounds and toxicological (safety) tests conducted to identify possible risks. The treatment with the most promising results is then moved into clinical trials. The results of clinical trials can make a difference in the care of patients by providing information about the benefits and risks of new therapeutic, preventive, or diagnostic products or interventions. Clinical trials also can add invaluable information about the benefits and safety of existing therapies, providing doctors and patients with predictable information for choosing between alternative treatments.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period. Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014.
- Track 4-1Cancer Clinical Trial
- Track 4-2Diabetic Clinical Trials
- Track 4-3Anti Viral Clinical Trials
- Track 4-4Other Pharmaceutical Clinical Trials
- Track 4-5Screening Trails
- Track 4-6Pilot Studies and feasbility studies
- Track 4-7Sequential Trails
- Track 4-8Multi Arm multi stage trails
- Track 4-9Prevention Trails
Pharmacy Forecast anticipates important developments in eight domains that are likely to challenge pharmacy practice head in hospitals and health systems. Its purpose is to enhance the effectiveness of leaders in hospital and health-system pharmacy practice by helping them to idea for the future. Pharmacy Forecast reports the results of a survey of trend watchers in health-system pharmacy,analyses predicted trends and presents more than 40 authoritative, actionable strategic recommendations to pharmacy practice leaders.
The global market for congestive heart failure pharmaceuticals was valued at nearly $11.2 billion in 2010. This market is expected to reach nearly $12.2 billion in 2011 and $18.6 billion in 2016, a compound annual growth rate (CAGR) of 8.9% between 2011 and 2016.
- Track 5-1Health System and Hospital Practices
- Track 5-2Ambulatory Care
- Track 5-3Quality Improvement
- Track 5-4Technology Applications
- Track 5-5Patient Empowerment
- Track 5-6Health-System Work Force
- Track 5-7Drug Development and Therapeutics
- Track 5-8Pharmacy Policies and Practices
The Companies express to regulatory issues in pharmaceutical manufacturing. Explore chemical and biotech process technology and equipment, dosage forms, facility engineering, and health, safety, and environment concepts. Study regulatory and legal deliberation. Learn how to ensure that methods, facilities and controls meet industry need for safety, effectiveness, identity, vigor, quality and purity. Drug manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be broken down into a sequence of unit operations, such as milling, granulation, coating, tablet pressing etc.
The market research available can provide investors and analysts credible information on the direction of pharmaceuticals, anaesthesia, drug delivery, pricing, regulations and policy being developed to ensure that knowledgeable and informed decisions are made regarding industry direction.
- Track 6-1Pharma Contract Manufacturing
- Track 6-2Pharma Manufacturing
- Track 6-3Pharmaceutical Machinery
Pharmaceutical R&D conduct the relationship between drug firms, drug costs, and the pace and direction of innovation. Average prices of new drug products have been growing much faster than the rate of inflation, and annual R&D spending has grown faster still. Nevertheless, introductions of inventive new drugs have slowed. At the same time, drug companies have been able to charge high retail cost for new drugs that are only incrementally different from older drugs whose prices have fallen. With consumers paying more for new drugs in the United States than almost any-where else in the world, and with the approach that the drug industry has become less innovative, many observers have wondered whether some kind of policy intervention is warranted.
- Track 7-1Pharma R&D Companies USA
- Track 7-2Pharma R&D Companies Philadelphia
- Track 7-3Generic Pharma Companies
- Track 7-4Biosimilars And Generics R&D
- Track 7-5Biomedical Modernization and Pharmaceutical Growth
- Track 7-6Drug Discovery and Development
- Track 7-7Technology Transfer in R&D Outsourcing
- Track 7-8Drug Discoveries From Natural Medicines by Unique Approaches
Regulatory Affairs is a field within regulated industries namely-pharmaceuticals, medical devices, energy and banking. It has precise meaning within healthcare industries namely- pharmaceuticals, medical devices, biologics and functional foods. Regulatory Affairs in pharma industry may be defined as "The interface between the pharmaceutical company and the regulatory branches across the world." Regulatory agency in the present context may be defined as "The competent government agency which is responsible for ensuring that medicines work and are acceptably safe."
The global market reached $80.7 billion in 2013 and should reach $83.6 billion in 2014. This market is expected to reach about $100.7 billion by 2019, registering a compound annual growth rate (CAGR) of 3.8% from 2014 to 2019.
- Track 8-1Regulatory Services
- Track 8-2Regulatory Consulting
- Track 8-3Regulatory Guidelines
- Track 8-4Global Regulatory Affairs Organization
- Track 8-5Global Regulatory Strategy
- Track 8-6Global Regulatory Agency Interaction
- Track 8-7Framework of Regulatory Affairs
- Track 8-8Regulatory Affairs in Clinical Trails
The Current Marketing practices in the pharmaceutical sector, examining both consumer and doctor oriented promotion. It presents examples of marketing practices and their impact on consumer and doctor behaviour. It identifies negative impact of these practices which include misleading advertising, disease shove and escalating costs. It goes on to argue the need for an independently monitored code of practice for marketers in the pharmaceutical sector and a great degree of consumer education for both end users and those prescribing drugs
The global market for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% between 2012 and 2017.
- Track 9-1Pharma Marketing Research
- Track 9-2USA Pharma Market
- Track 9-3Global Pharma Market
- Track 9-4Multichannel Marketing
- Track 9-5Customer Relationship Marketing
- Track 9-6Omni Channel Trends Tactics and Ideas
- Track 9-7Digital Marketing Excellence
- Track 9-8Customer Centricity: The importance of being Customer Centri
- Track 9-9Self-Regulations
The global telemedicine market is expected to grow from $9.8 billion in 2010 to $11.6 billion in 2011, and to $27.3 billion in 2016, a compound annual growth rate (CAGR) of 18.6% over the next five years.
- Track 10-1Online Pharmacy
- Track 10-2Community Pharmacy
- Track 10-3Compounding Pharmacy
- Track 10-4Mail order Pharmacy
- Track 10-5Overseas Pharmacy
The inventive pharmaceutical industry in the United States produces chemically-derived drugs developed as a result of expanded R&D and clinical trials in both humans and animals. The innovator relies on patents and other forms of rational property rights to justify the investment required to deliver a product to market (the U.S. patent term is 20 years). The pharmaceutical industry is heavily reliant on the development of new molecules to replace the revenue stream of older drugs that have come to the expiration of their patent terms. Several large multinationals produce the majority of inventive pharmaceuticals globally, but they have come to confide more heavily on research performed by industry partners, including smaller, inventive manufacturers. Pricing of innovative pharmaceuticals is designed to recapture R&D expenditures.
The global market for process analytical technology (PAT) instrumentation in 2013 was $305.1 million, which is expected to reach about $326.3 million by year-end 2014. The projected PAT instrumentation market is expected to be valued at around $450.6 million by 2019 at a compound annual growth rate (CAGR) of 6.7% for the period of 2014 to 2019.
- Track 11-1Drug Discovery
- Track 11-2Pharmaceutical Packaging
- Track 11-3Quality Control
- Track 11-4Quality Assurance
- Track 11-5GMP & cGMP
- Track 11-6Quality by Design
- Track 11-7Quality Risk Assessment
A drug is any substance other than food, that when inhaled, injected, smoked, consumed, absorbed via a patch on the skin or dissolved under the tongue causes a physiological change in the body.
In pharmacology, a pharmaceutical drug or medicine, is a chemical substance used to treat, cure, prevent, diagnose a disease or promote well-being. Traditionally drugs were obtained through extraction from medicinal plants, but more recently also by organic synthesis. Pharmaceutical drugs may be used for a limited duration, or on a regular basis for chronic disorders.
Pharmaceutical drugs are often classified into drug classes—groups of related drugs that have similar chemical structures, the same mechanism of action (binding to the same biological target), a related mode of action, and that are used to treat the same disease.[verification needed] The Anatomical Therapeutic Chemical Classification System (ATC), the most widely used drug classification system, assigns drugs a unique ATC code, which is an alphanumeric code that assigns it to specific drug classes within the ATC system. Another major classification system is the Biopharmaceutics Classification System. This classifies drugs according to their solubility and permeability or absorption properties
- Track 12-1Drug Discovery
- Track 12-2Drug Formulation
- Track 12-3Drug Interaction
- Track 12-4Drug Therapy
- Track 12-5Adverse Drug Reactions
- Track 12-6Drug Abuse and Drug Addiction
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, clinical trials on humans, and may include the step of obtaining regulatory approval to market the drug.
- Track 13-1Therapeutic drug monitoring
- Track 13-2Recent Innovations in Drug delivery technology
- Track 13-3Drug formulation development
- Track 13-4Drug interactions
- Track 13-5Clinical Drug Development
- Track 13-6Drug Delivery Systems
Pharmacovigilance (PV or PhV), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.
- Track 14-1Significance of Pharmacovigilance
- Track 14-2Pharmacovigilance and Health care System
- Track 14-3Methods of Pharmacovigilance
- Track 14-4Good Pharmacovigilance Practice
Pharmaceutical Analysis is an Analytical Method used to determination the quality and quantity of the pharmaceutical products. It also gives the information about the purity and safety of the products. Briefly it can be described as it identifies, determines, quantifies, purifies and separates the active compound from the mixture.
- Track 15-1Chromatographic techniques
- Track 15-2Special techniques
- Track 15-3Quality control and Quality assurance
- Track 15-4Validation methods
- Track 15-5Quantitative and qualitative analysis in the drug screening process
Entrepreneurs are usually viewed as individuals who take consequential risks to go out and start new companies, but most pharmacists go to work for existence that are already established, such as a community pharmacy or hospital.